PTGS2 and cancer: The authors have shown that nimesulide, a selective inhibitor of COX-2 (which as noted earlier, is expressed by PSCs and implicated in PSC-cancer interactions), retards the progression of pancreatic cancer precursor lesions in a GEM model.